{"id":4544,"date":"2018-07-13T10:47:39","date_gmt":"2018-07-13T14:47:39","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4544"},"modified":"2018-07-13T10:47:39","modified_gmt":"2018-07-13T14:47:39","slug":"establishment-labs-holdings-inc-ipo-preview-esta","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/establishment-labs-holdings-inc-ipo-preview-esta\/","title":{"rendered":"Establishment Labs Holdings Inc. #IPO Preview $ESTA"},"content":{"rendered":"

\"ESTA\"<\/a><\/p>\n

Company: Establishment Labs Holdings Inc.
\nSymbol: ESTA
\nDescription: They are a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market.
\nTrade Date: 7\/19
\nShares: 3.125 million
\nPrice Range: $15.00-$17.00
\nUnderwriter(s): Jefferies, Cowen, BTIG
\nTerms Added: 7-9-18<\/p>\n

Link to Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>:\u00a0They are a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market. Their line of silicone gel-filled breast implants, branded as Motiva Implants, is the centerpiece of their MotivaImagine medical technology platform. Post-market surveillance data, which was not generated in connection with an FDA PMA approval study and was self-collected rather than collected at mandatory follow-ups, and published third-party data indicates that Motiva Implants show low rates of adverse events (including rupture, capsular contracture, and safety related reoperations) that they believe compare favorably with those of their competitors. They believe the proprietary technologies that differentiate their Motiva Implants enable improved safety and aesthetic outcomes and have helped drive their revenue growth. Their MotivaImagine platform enables surgical techniques that they promote as Motiva branded surgeries. They have developed other complementary products and services on their MotivaImagine platform, which are aimed at further enhancing patient outcomes.<\/p>\n

 <\/p>\n

Financials: \u00a0<\/strong>Their revenue for\u00a02015,\u00a02016\u00a0and\u00a02017\u00a0was\u00a0$9.6 million,\u00a0$19.8 million\u00a0and\u00a0$34.7 million, respectively, an increase of $10.2 million, or 106%, in 2016 compared to 2015, and an increase of\u00a0$14.9 million, or\u00a075%, in\u00a02017\u00a0compared to\u00a02016.\u00a0Net losses increased from\u00a0$1.6 million in 2015 to\u00a0$22.2 million\u00a0in\u00a02016, and further increased to\u00a0$34.9\u00a0million\u00a0in\u00a02017, an increase of\u00a057%\u00a0compared to 2016.\u00a0As of\u00a0December\u00a031, 2017, they had an accumulated deficit of\u00a0$67.9 million.<\/p>\n

Their revenue for\u00a0the three months ended\u00a0March\u00a031, 2017\u00a0and 2018\u00a0was\u00a0$6.9 million\u00a0and\u00a0$14.8 million, respectively, an increase of\u00a0$7.9 million, or\u00a0114%.\u00a0Net losses increased from\u00a0$5.0 million\u00a0for the three months ended\u00a0March\u00a031, 2017\u00a0to\u00a0$6.5 million\u00a0for the three months ended\u00a0March\u00a031, 2018.\u00a0As of\u00a0March\u00a031, 2018, they had an accumulated deficit of\u00a0$74.4 million.<\/p>\n

\"Screen<\/a><\/p>\n

 <\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: Establishment Labs Holdings Inc. Symbol: ESTA Description: They are a medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market. Trade Date: 7\/19 Shares: 3.125 million Price Range: $15.00-$17.00 Underwriter(s): Jefferies, Cowen, BTIG Terms Added: 7-9-18 Link to Prospectus Link to Retail Roadshow Business:\u00a0They are[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1524],"class_list":["post-4544","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-esta"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4544"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4544\/revisions"}],"predecessor-version":[{"id":4547,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4544\/revisions\/4547"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}